The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain Injury
NCT ID: NCT00929448
Last Updated: 2012-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2008-07-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis of this study is that the hypogammaglobulinemia from the immune dysfunction and the induction of NF-kB from the inflammatory process are, in part, responsible for the development of pneumonia and other infectious complications identified after TBI. This study has two specific aims: The primary specific aim of this study is to determine the association between serum immunoglobulin or NF-kB levels and the development of pneumonia in patients suffering from traumatic brain injury (TBI). The secondary specific aim of this study is to determine the relative contribution of clinical variables such as APACHE II-III Score and Injury Severity Score as compared to immunological variables (serum immunoglobulins and NF-kB) to the development of pneumonia in patients suffering from TBI.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immunoglobulin
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to ICU in Capital Health region with a TBI and \> 1 of the following:
* An initial resuscitated (Sys BP\>90 mmHg and O2 Sat \>90%) GSC of ≤ 8
* A post resuscitation (Sys BP\>90 mmHg and O2 Sat \>90%) GCS at presentation to the hospital of ≤ 8 in the absence of sedation
* A post resuscitation (Sys BP\>90 mmHg and O2 Sat \>90%) GCS within 72 hrs of hospital admission of ≤ 8 in the absence of sedation
* Intracranial pressure monitoring
* Decompressive craniectomy
* Presence of subfalcine, uncal, or supratentorial herniation either clinically or radiologically
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Alexandra Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Demetrios J. Kutsogiannis
MD, MHS, FRCPC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Demetrios Kutsogiannis, MD
Role: PRINCIPAL_INVESTIGATOR
Royal Alexandra Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Alexandra Hospital
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
iTBI2009
Identifier Type: -
Identifier Source: org_study_id